Deuterated 2-propylpentanoic acid compounds

A pharmaceutically acceptable composition comprising:

• a. a compound of the Formula I:
• or a pharmaceutically acceptable salt thereof, wherein:
• each of R1 and R2 independently for each occurrence is —CH2CH2CH3, wherein —CH2CH2CH3 is optionally substituted with 1 to 7 deuterium atoms;
• R3 is hydrogen or deuterium;
• and
• Y is OH or OD,
• provided that if each of R1 and R2 is —CH2CH2CH3 or —CH2—CHD-CH2D, then R3 is deuterium;
• further provided that if R1 is —CH2CH2CH3 and R2 is —CD2CD2CD3, then R3 is deuterium;
• b. a second therapeutic agent selected from the group consisting of sunitinib, sorafenib, dasatinib, erlotinib, lapatinib, lenalidomide, temozolomide, 5-fluorouracil, epirubicin, cyclophosphamide, karenitecin, decitabine, aripiprazole, olanzapine, lamotrigine, risperidone, quetiapine, carbamazepine, and phenyloin;
• and
• c. a pharmaceutically acceptable carrier.

A pharmaceutically acceptable composition comprising:

• a. a compound of the formula:
• or a pharmaceutically acceptable salt thereof;
• b. a second therapeutic agent selected from the group consisting of sunitinib, sorafenib, dasatinib, erlotinib, lapatinib, lenalidomide, temozolomide, 5-fluorouracil, epirubicin, cyclophosphamide, karenitecin, decitabine, aripiprazole, olanzapine, lamotrigine, risperidone, quetiapine, and phenyloin;
• and
• c. a pharmaceutically acceptable carrier.

A pharmaceutically acceptable composition comprising:

• a. a compound of the formula
• or a pharmaceutically acceptable salt thereof;
• b. a second therapeutic agent selected from the group consisting of sunitinib, sorafenib, dasatinib, erlotinib, lapatinib, lenalidomide, temozolomide, 5-fluorouracil, epirubicin, cyclophosphamide, karenitecin, decitabine, aripiprazole, olanzapine, lamotrigine, risperidone, and quetiapine;
• and
• c. a pharmaceutically acceptable carrier.

A compound of the Formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• each of R1 and R2 independently for each occurrence is —CH2CH2CH3, wherein —CH2CH2CH3 is optionally substituted with 1 to 7 deuterium atoms;
• R3 is hydrogen or deuterium;
• and
• Y is OH or OD,
• provided that if each of R1 and R2 is —CH2CH2CH3 or —CH2CHD-CH2D, then R3 is deuterium;
• further provided that if R1 is —CH2CH2CH3 and R2 is —CD2CD2CD3, then R3 is deuterium;
• or a pharmaceutical composition comprising the compound or salt for use in treating a disease or condition selected from epilepsy, bipolar disorder, migraine, schizophrenia, autism, mood disorder, major depressive disorder, borderline personality disorder, intermittent explosive disorder, ADHD, dementia, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, bronchial asthma, post-traumatic seizure disorder, spinal muscular atrophy, progressive supranuclear palsy (PSP), opiate dependence, drug dependence, substance withdrawal syndrome, nasopharyngeal carcinoma, acute myelogenous leukemia, myelodysplastic syndromes, lymphoma, advanced neoplasms, cervical cancer, breast cancer, malignant melanoma, Kaposi's sarcoma, lung cancer, neurologic cancer, basal cell carcinoma, squamous cell carcinoma, keratoacanthoma, Bowen disease, cutaneous T-cell lymphoma, non-small cell lung cancer, pre-malignant lesions, inflammations of the skin and/or mucosa, exposure to UV light, and sunburn.